Iqvia price target raised to $297 from $286 at Truist

Truist raised the firm’s price target on Iqvia to $297 from $286 and keeps a Buy rating on the shares. The firm is updating its model to reflect the company’s 10-K disclosure regarding the life sciences industry generating about $1.63T in revenues in 2023, up from $1.48T in 2022, along with its expectations that spending on pharmaceuticals in emerging markets is expected to expand at a 5%-8% CAGR through 2028, the analyst tells investors in a research note.